Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Horizon Technology Finance Announces First Quarter 2023 Financial Results PR Newswire FARMINGTON, Conn., May 2, 2023 - First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share...
Sélectionnée par le gouvernement canadien pour recevoir un financement supplémentaire, portant le soutien à un total de 10 millions de dollars à ce jour pour le développement clinique et la...
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious...
Rapidly progressing DPX-COVID-19, including Health Canada agreement on Phase 1 clinical study design protocol, with preliminary results expected in fall 2020 Confirmed $4.75M of non-dilutive...
Ces subventions d’un total de 4,75 millions soutiendront la fabrication du vaccin et l’étude clinique de phase 1 IMV Inc. (Nasdaq: IMV; TSX: IMV), une société biopharmaceutique (la « Société »...
Contribution totalling Cdn$4.75 Million will support Phase 1 clinical development and manufacturing of DPX-COVID-19 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company...
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against...
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will present at BTIG’s Virtual...
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced the...
Reçoit l’accord de Santé Canada à l’égard du design d’un essai clinique de phase 1, lequel comprendra aussi une cohorte d'adultes âgés de 56 ans et plus Formulation cGMP et développement du...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 4 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 12 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 26 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 52 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 156 | -15.48 | -93.2530120482 | 16.6 | 19.3 | 0.62 | 20466 | 7.7944446 | CS |
| 260 | -40.78 | -97.3269689737 | 41.9 | 92.5 | 0.62 | 79151 | 38.26990427 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
